Objective: Since the discovery of ionizing radiation, clinicians have evaluated X-ray images separately from the patient. The objective of this study was to investigate the accuracy and repeatability of a new technology which seeks to resolve this historic limitation by projecting anatomically correct X-ray images on to a person's skin.
Methods: A total of 13 participants enrolled in the study, each having a pre-existing anteroposterior lumbar X-ray. Each participant's image was uploaded into the Hololens Mixed reality system which when worn, allowed a single examiner to view a participant's own X-ray superimposed on the participant's back. The projected image was topographically corrected using depth information obtained by the Hololens system then aligned via existing anatomic landmarks. Using this superimposed image, vertebral levels were identified and validated against spinous process locations obtained by ultrasound. This process was repeated 1-5 days later. The projection of each vertebra was deemed to be "on-target" if it fell within the known morphological dimensions of the spinous process for that specific vertebral level.
Results: The projection system created on-target projections with respect to individual vertebral levels 73% of the time with no significant difference seen between testing sessions. The average repeatability for all vertebral levels between testing sessions was 77%.
Conclusion: These accuracy and repeatability data suggest that the accuracy and repeatability of projecting X-rays directly on to the skin is feasible for identifying underlying anatomy and as such, has potential to place radiological evaluation within the patient context. Future opportunities to improve this procedure will focus on mitigating potential sources of error.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377589 | PMC |
http://dx.doi.org/10.7717/peerj.6333 | DOI Listing |
Alzheimers Dement
December 2024
Clinical Memory Research Unit, Lund University, Lund, Sweden.
Background: Fluid biomarkers represent an informative and cost-effective way to detect and monitor Alzheimer's disease (AD). However, as we recently showed, the overall proteome average in CSF exhibits a non-disease related average signal (inter-individual variability), which can reduce the precision of concentration based CSF AD biomarkers. Now, we therefore investigate if several already high performing CSF and plasma AD biomarkers can be improved by normalizing their concentration to a reference protein (e.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands.
Background: Synaptic dysfunction plays an important role in Alzheimer's disease (AD) and cognitive decline. We investigated the association between cerebrospinal fluid (CSF) synaptic protein levels and quantitative EEG (qEEG) measures, two modalities to measure synaptic dysfunction in AD pathology. We assessed combined and independent prognostic value of both modalities for cognitive decline along the AD continuum.
View Article and Find Full Text PDFBackground: Amyloid and alpha synuclein proteins are brain biomarkers of different neurodegenerative diseases, many years before symptoms. We have shown that imaging dye-free with polarized light makes retinal amyloid deposits visible as a biomarker, in the brain, of amyloid and Alzheimer's disease (AD) severity. Here, we extend to presumed retinal alpha synuclein deposits in those with brain pathology consistent with alpha synuclein.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Mallinckrodt Institute of Radiology, Washington University School of Medicine in St Louis, St Louis, MO, USA.
Background: Application of the amyloid/tau/neurodegeneration (ATN) framework is varied, with some research relying on binary assessment of biomarkers and some using continuous or multidimensional measures. There are few investigations which directly evaluate how differing operationalizations of ATN affect prediction of cognitive impairment.
Method: We selected 473 individuals from ADNI who received PET imaging for amyloid-beta (AV-45) and tau (flortaucipir), as well as volumetric MRI.
Background: The retina is a novel biomarker target for examining AD pathology, specifically beta-amyloid (Aβ). Though relationship between retinal Aβ and standard preclinical AD biomarkers (cerebral Aβ PET) remains understudied, retinal inclusion bodies (IB, strongly hypothesized to contain fibrillar Aβ), predict cerebral Aβ load in the anterior cingulate cortex (ACC). This study explored the value of retinal IB as a preclinical AD biomarker, comparing number and surface area (SA) of IB with cerebral Aβ PET.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!